PRMTs, like the coactivator-associated arginine methyl-transferase (CARM1) and PRMT5, have been described to play an important role in cancer as their expression increases in breast and prostate cancers, for CARM1, and lymphoma, for PRMT5. This evidence concerns the gene CARM1 and prostate carcinoma.